Ghetie M A, Vitetta E S
Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas 75235-8576.
Curr Opin Immunol. 1994 Oct;6(5):707-14. doi: 10.1016/0952-7915(94)90073-6.
Immunotoxin (IT) research has been ongoing for 15 years. During the past 2 years, work has focused on several areas: on improvements and developments in first- and second-generation ITs; the preparation of new immunotoxin constructs with anti-tumor activity; novel animal models for preclinical evaluation of immunotoxins; and clinical trials, which are now entering Phase II or III in humans.